The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
PT-141 · Bremelanotide · Vyleesi · PT141
Pilot studies, observational data, or smaller RCTs. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.
Same compound, route-specific context. Switch forms instead of opening separate pages.
Use the route notes below to match form, goal, and evidence quality.
Hard-stop risk to review first: ABSOLUTE CONTRAINDICATION: UNCONTROLLED HYPERTENSION AND CARDIOVASCULAR DISEASE Bremelanotide transiently increases blood pressure after…
Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.
PT-141 / bremelanotide is the most rigorously evidenced compound in this reference and also the one whose community use deviates most completely from the evidence base. The FDA approved it for women. The community uses it primarily for men. The evidence quality for the approved indication is exceptional. The evidence quality for the primary community use is solid but incomplete.
The central tension resolved: PT-141 exists in two parallel realities. As Vyleesi, it is an FDA-approved pharmaceutical for premenopausal women with HSDD, backed by two Phase 3 RCTs with 1,247 participants, a defined safety profile with documented contraindications, and physician-supervised access. As PT-141, it is a research chemical used primarily by men for erectile dysfunction and libido enhancement, off-label from the approved indication, with Phase 2 evidence showing 34% response in PDE5 non-responders, and community consensus reporting consistent efficacy at 1-2 mg SubQ doses. These are the same molecule. They are not the same evidence context, the same user, the same indication, or the same level of regulatory oversight.
The strongest argument for PT-141: it is the only compound in this reference with a mechanistic reason to believe it provides something that nothing else does. PDE5 inhibitors improve blood flow. PT-141 creates the desire and arousal that blood flow alone cannot produce. For men with psychogenic ED, low libido, or PDE5 inhibitor treatment failure, the central MC4R mechanism addresses the deficit that peripheral vascular agents cannot touch. The Phase 2 data shows 34% response in the hardest-to-treat population. The mechanism is independently confirmed. The safety profile in the Phase 3 data is well-characterized, which makes the contraindications clear rather than uncertain.
The strongest argument for caution: the blood pressure increase is mechanistically inherent and cannot be avoided. For anyone with cardiovascular disease or uncontrolled hypertension, PT-141 is an absolute contraindication — not a question of careful dosing, a question of not using it at all. The hyperpigmentation risk at 1% may sound small but is potentially permanent in half of affected individuals. The community's use pattern (men, off-label, research chemical, variable doses) operates outside the safety monitoring infrastructure that the FDA approval was built on.
The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.
The Pure Active Isomer in Clomid. The Drug That Raised Testosterone as Well as TRT While Preserving Fertility — and Still Failed FDA Approval. The Zuclomiphene Problem: Why the Racemic Mixture Causes Side Effects Pure Enclomiphene Shouldn't. The NDA That Died in 2021. How It Differs from TRT, HCG, and Gonadorelin for Male Hypogonadism. The 2025 Meta-Analysis: +273 ng/dL Testosterone vs Placebo.
The Nobel Prize Decapeptide (Schally and Guillemin, 1977). The Compound That Is Stimulatory When Pulsatile and Suppressive When Continuous — From the Same Receptor. The Most Pharmacologically Nuanced Chapter in this reference. Why the FDA's March 2020 HCG Compounding Ban Changed TRT Practice Overnight. Gonadorelin vs HCG: The Fertility Preservation Head-to-Head. Why FSH Matters for Spermatogenesis. The Pulsatile Dosing Problem in Practice.
FDA-Approved for Fertility and Male Hypogonadism. The Most Important Hormone in Post-Cycle Therapy. The Active Ingredient in the Simeons 500-Calorie Diet — a Fraud With Its Own FDA Warning. WADA S2 Banned. A Tumor Marker. Three Completely Different Identities in One Glycoprotein.